Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Cytochrome P-450 CYP2C19/genetics"'
Autor:
Kranendonk, J, Willems, L H, Vijver-Coppen, Rj van der, Coenen, M, Adang, E, Donders, R, Zeebregts, C J, Deneer, V, Reijnen, Mmpj, Kramers, C, Warlé, M C, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
American heart journal, 254, 141-148. Mosby Inc.
American Heart Journal, 254, 141. Mosby Inc.
American Heart Journal, 254, 141-148
American Heart Journal, 254, 141-148. MOSBY-ELSEVIER
American Heart Journal, 254, pp. 141-148
American Heart Journal, 254, 141. Mosby Inc.
American Heart Journal, 254, 141-148
American Heart Journal, 254, 141-148. MOSBY-ELSEVIER
American Heart Journal, 254, pp. 141-148
Background: Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD). Clopidogrel itself is inactive and metabolism is dependent on the CYP2C19 enzyme. About 30% o
Autor:
Brahim Achour, Pauline Gosselin, Jean Terrier, Yvonne Gloor, Zubida M. Al‐Majdoub, Thomas M. Polasek, Youssef Daali, Amin Rostami‐Hodjegan, Jean‐Luc Reny
Publikováno v:
Achour, B, Gosselin, P, Terrier, J, Gloor, Y, Al-Majdoub, Z M, Polasek, T M, Daali, Y, Rostami-Hodjegan, A & Reny, JL 2022, ' Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities ', Clinical Pharmacology & Therapeutics, vol. 111, no. 6, pp. 1268-1277 . https://doi.org/10.1002/cpt.2576
Precision dosing strategies require accounting for between-patient variability in pharmacokinetics together with subsequent pharmacodynamic differences. Liquid biopsy is a valuable new approach to diagnose disease prior to the appearance of clinical
Autor:
Amein K. Al-Ali, Rudaynah A. Alali, Folkert W. Asselbergs, Chittibabu Vatte, Abdullah M. Al-Rubaish, Mohammed M. Sulieman, Abdullah M. Alshehri, Fahad Al-Muhanna, Cyril Cyrus, Daniel M.F. Claassens, Mohammed Almansori, Rania M. Khalil, Khalid A. Al-Faraidy, Bao-Li Loza
Publikováno v:
International journal of cardiology, 343, 15-20. Elsevier Ireland Ltd
Background ST-segment elevation myocardial infarction (STEMI) patients are treated with dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor. Clopidogrel is widely used in these patients in several areas worldwide, such as Middle East,
Autor:
Okhuijsen-Pfeifer, C., van der Horst, M. Z., Bousman, C. A., Lin, B., van Eijk, K. R., Ripke, S., Ayhan, Y., Babaoglu, M. O., Bak, M., Alink, W., van Beek, H., Beld, E., Bouhuis, A., Edlinger, M., Erdogan, I. M., Ertuğrul, A., Yoca, G., Everall, I. P., Görlitz, T., van Amelsvoort, T., Bartels-Velthuis, A. A., Bruggeman, R., Cahn, W., Guloksuz, S., de Haan, L., Kahn, R. S., Schirmbeck, F., Simons, C. J. P., van Os, J., Alizadeh, B. Z., Luykx, J. J., Rutten, B. P. F., van Winkel, R., Grootens, K. P., Gutwinski, S., Hallikainen, T., Jeger-Land, E., de Koning, M., Lähteenvuo, M., Legge, S. E., Leucht, S., Morgenroth, C., Müderrisoğlu, A., Narang, A., Pantelis, C., Pardiñas, A. F., Oviedo-Salcedo, T., Schneider-Thoma, J., Schreiter, S., Repo-Tiihonen, E., Tuppurainen, H., Veereschild, M., Veerman, S., de Vos, M., Wagner, E., Cohen, D., Bogers, J. P. A. M., Walters, J. T. R., Yağcıoğlu, A. E. Anil, Tiihonen, J., Hasan, A.
Publikováno v:
Translational Psychiatry, 12(1):145. Nature Publishing Group
Translational psychiatry, 12(1):145. Nature Publishing Group
Translational psychiatry, 12(1):145. Nature Publishing Group
Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response is highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15d35979803fbaf570d9245558fcc0da
https://research.rug.nl/en/publications/68c11f0b-1d30-47b1-b8cc-469ae7b6003c
https://research.rug.nl/en/publications/68c11f0b-1d30-47b1-b8cc-469ae7b6003c
Autor:
Abdullah M. Al-Rubaish, Fahad A. Al-Muhanna, Abdullah M. Alshehri, Abdulla A. Alsulaiman, Majed M. Alabdulali, Fahad Alkhamis, Abdulallh S. Alamri, Rudaynah A. Alali, Mohammed S. Akhtar, Cyril Cyrus, Daniel M.F. Claassens, Folkert W. Asselbergs, Amein K. Al-Ali
Publikováno v:
Drug Metabolism and Personalized Therapy, 37(1), 35-40. Walter de Gruyter GmbH
Objectives To mitigate the incidence of recurrent stroke in patients, dual antiplatelet therapy comprising aspirin and clopidogrel is usually administered. Clopidogrel is a prodrug and its bioactivation is catalyzed by cytochrome P450 (CYP)2C19. The
Autor:
Claire, Grosu, Olga, Trofimova, Mehdi, Gholam-Rezaee, Marie-Pierre F, Strippoli, Ferath, Kherif, Antoine, Lutti, Martin, Preisig, Bogdan, Draganski, Chin B, Eap
Publikováno v:
Translational Psychiatry
Translational psychiatry, vol. 12, no. 1, pp. 316
Translational psychiatry, vol. 12, no. 1, pp. 316
Given controversial findings of reduced depressive symptom severity and increased hippocampus volume in CYP2C19 poor metabolizers, we sought to provide empirical evidence from a large-scale single-center longitudinal cohort in the community-dwelling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::70632c69d36c91caede2c5b0068a672b
https://hdl.handle.net/21.11116/0000-000A-EF91-521.11116/0000-000A-EF93-3
https://hdl.handle.net/21.11116/0000-000A-EF91-521.11116/0000-000A-EF93-3
Autor:
Claassens, Daniel M F, Vos, Gerrit J A, Bergmeijer, Thomas O, Hermanides, Renicus S, van 't Hof, Arnoud W J, van der Harst, Pim, Barbato, Emanuele, Morisco, Carmine, Tjon Joe Gin, Richard M, Asselbergs, Folkert W, Mosterd, Arend, Herrman, Jean-Paul R, Dewilde, Willem J M, Janssen, Paul W A, Kelder, Johannes C, Postma, Maarten J, de Boer, Anthonius, Boersma, Cornelis, Deneer, Vera H M, Ten Berg, Jurriën M, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
New England Journal of Medicine, 381(17), 1621-1631. MASSACHUSETTS MEDICAL SOCIETY
New England Journal of Medicine, 381(17), 1621-1631. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine, 381, 1621. Massachussetts Medical Society
New England Journal of Medicine, 381(17), 1621. Massachussetts Medical Society
New England Journal of Medicine, 381(17), 1621-1631. MASSACHUSETTS MEDICAL SOC
New England Journal of Medicine, 381, 1621. Massachussetts Medical Society
New England Journal of Medicine, 381(17), 1621. Massachussetts Medical Society
BackgroundIt is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y(12) inhibitors.MethodsWe conducted a randomized, open-label, assessor-blinded trial in which patie
Autor:
Vera H.M. Deneer, Renicus S Hermanides, Carmine Morisco, Richard M. Tjon Joe Gin, Gerrit J.A. Vos, Arend Mosterd, Pim van der Harst, Daniel M.F. Claassens, Jean-Paul R. Herrman, Johannes C. Kelder, Willem Dewilde, Paul W.A. Janssen, Bakhtawar K. Mahmoodi, Arnoud W J van 't Hof, Jurriën M. ten Berg, Folkert W. Asselbergs, Thomas O. Bergmeijer, Emanuele Barbato
Publikováno v:
Circulation-Cardiovascular interventions, 14(4):009434, 402-411. LIPPINCOTT WILLIAMS & WILKINS
Circulation. Cardiovascular interventions, 14(4). Lippincott Williams and Wilkins
Circulation: Cardiovascular Interventions, 14(4), 402. Lippincott Williams and Wilkins Ltd.
Circulation-Cardiovascular Interventions, 14(4):009434, 402-411. LIPPINCOTT WILLIAMS & WILKINS
Circulation. Cardiovascular interventions, 14(4). Lippincott Williams and Wilkins
Circulation: Cardiovascular Interventions, 14(4), 402. Lippincott Williams and Wilkins Ltd.
Circulation-Cardiovascular Interventions, 14(4):009434, 402-411. LIPPINCOTT WILLIAMS & WILKINS
Background: Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary Percutaneous Coronary Intervention [PCI]) showed that in patients with pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54ef6016a26fcea7ac724e7cf6c3723
https://research.rug.nl/en/publications/c88d7bed-0522-46be-abfa-3331f07b3fe4
https://research.rug.nl/en/publications/c88d7bed-0522-46be-abfa-3331f07b3fe4
Publikováno v:
Rath, C L, Jørgensen, N R & Wienecke, T 2020, ' Clopidogrel responder status is uninfluenced by CYP2C19∗2 in Danish patients with stroke ', PLoS ONE, vol. 15, no. 12, e0236260 . https://doi.org/10.1371/journal.pone.0236260
Rath, C L, Jorgensen, N R & Wienecke, T 2020, ' Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke ', PLOS ONE, vol. 15, no. 12, e0236260 . https://doi.org/10.1371/journal.pone.0236260
PLoS ONE, Vol 15, Iss 12, p e0236260 (2020)
PLoS ONE
Rath, C L, Jorgensen, N R & Wienecke, T 2020, ' Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke ', PLOS ONE, vol. 15, no. 12, e0236260 . https://doi.org/10.1371/journal.pone.0236260
PLoS ONE, Vol 15, Iss 12, p e0236260 (2020)
PLoS ONE
Background Antiplatelet therapy is a cornerstone of secondary stroke prevention, but the responsiveness to antiplatelet medication varies among patients. Clopidogrel is a pro-drug that requires hepatic transformation to reach its active metabolite. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b31e27f0a034dae1328db6ae0459b1
https://curis.ku.dk/portal/da/publications/clopidogrel-responder-status-is-uninfluenced-by-cyp2c192-in-danish-patients-with-stroke(5eb8beca-932f-4541-b056-8ea52a9ffb83).html
https://curis.ku.dk/portal/da/publications/clopidogrel-responder-status-is-uninfluenced-by-cyp2c192-in-danish-patients-with-stroke(5eb8beca-932f-4541-b056-8ea52a9ffb83).html
Autor:
Michiel Voskuil, J. Wouter Jukema, Arnoud W J van 't Hof, Ton Heestermans, Gerrit J.A. Vos, Pim van der Harst, Richard M. Tjon Joe Gin, Marieke E. Gimbel, Sjoerd H. Hofma, A. Mosterd, Clemens von Birgelen, Jurriën M. ten Berg, Evelyn A. de Vrey, Folkert W. Asselbergs, Emanuele Barbato, Vera H.M. Deneer, Renicus S Hermanides, Thomas O. Bergmeijer, Willem Dewilde, Jean-Paul R. Herrman, Carmine Morisco, Frank R. den Hartog, Daniel M.F. Claassens, Bakhtawar K. Mahmoodi, Reinier A. Waalewijn
Publikováno v:
International Journal of Cardiology, 334, 10-17. Elsevier Ireland Ltd
International journal of cardiology, 334, 10-17. Elsevier Ireland Ltd
International Journal of Cardiology, 334, 10-17. ELSEVIER IRELAND LTD
International Journal of Cardiology, 334, 10. Elsevier Ireland Ltd.
International journal of cardiology, 334, 10-17. Elsevier Ireland Ltd
International Journal of Cardiology, 334, 10-17. ELSEVIER IRELAND LTD
International Journal of Cardiology, 334, 10. Elsevier Ireland Ltd.
Background: Patients with acute coronary syndrome (ACS) who are carrying CYP2C19 loss-of-function alleles derive less benefit from clopidogrel treatment. Despite this, in elderly patients, clopidogrel might be preferred over more potent P2Y12 inhibit